Gout patients in the south get a new tool: storytelling on a tablet

NCT ID NCT04075903

Ongoing Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a culturally tailored storytelling video, shown on a tablet, can help 200 gout patients—especially African Americans in the Southeast—better understand their condition and stick with long-term treatments like medication, diet, and exercise. The goal is to reduce painful flares and improve overall care. Participants are recruited from emergency departments and compared to those receiving usual care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: storytelling video
What this could lead to: If it works, this could improve gout management and reduce flares in minority patients by making health information more relatable and easier to act on.
What could go wrong: This is a small, early-stage behavioral study with no drug involved, so results may not be dramatic or widely applicable. Success depends on patients' willingness to change habits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GOUT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gout

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GOUT

Contacts and locations

Locations

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
MetroHealth Medical Center

Cleveland, Ohio, 44109, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35294, United States
University of Iowa Hospitals and Clinics

Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.